Skip to main content

Table 2 Associations between HLE-E expression and histopathological parameters

From: HLA-E expression in cervical adenocarcinomas: association with improved long-term survival

   HLA-E low HLA-E high P value
   n (%) n (%)  
Histology SCC 42 (53) 37 (47) 0.010
(n = 192) ASC 20 (53) 18 (47)  
  AC 23 (31) 52 (69)  
Tumour stage FIGO I 72 (44) 93 (56) 0.662
(n = 192) FIGO II 13 (48) 14 (52)  
HPV Negative 7 (44) 9 (56) 0.965
(n = 192) Positive 78 (44) 98 (56)  
HPV type specific HPV 16 42 (43) 56 (57) 0.949
(n = 151) HPV 18 23 (43) 30 (57)  
Tumour size <40 mm 56 (45) 69 (55) 0.997
(n = 183) > = 40 mm 26 (45) 32 (55)  
Infiltration depth <15 mm 47 (40) 70 (60) 0.112
(n = 186) > = 15 mm 36 (52) 33 (48)  
LVSI Negative 32 (38) 53 (62) 0.045
(n = 174) Positive 47 (53) 42 (47)  
Resection margins Tumour free 62 (42) 86 (58) 0.178
(n = 191) Tumour positive 23 (54) 20 (47)  
Parametria involvement Tumour free 76 (43) 100 (57) 0.314
(n = 192) Infiltrated 9 (56) 7 (44)  
Lymph nodes Negative 60 (43) 81 (57) 0.426
(n = 192) Positive 25 (49) 26 (51)  
Adjuvant radiotherapy No 37 (39) 59 (61) 0.110
(n = 192) Yes 48 (50) 48 (50)  
  1. Human leukocyte antigen E (HLA-E) expression scores are dichotomized by the median; a final score ≥6 indicates high HLA-E expression, and a final score <6 indicates low to negative HLA-E expression. For nine, six, eighteen, and one cases the tumour size, depth of infiltration, LVSI (lymph-vascular space invasion), and tumour positivity of resection margins, respectively, could not be identified. P values were calculated using the Pearson Chi-Square test. P values in bold type were considered statistically significant (P < 0.05). SCC, cervical squamous cell carcinoma; ASC, cervical adenosquamous carcinoma; AC, cervical adenocarcinoma; FIGO, International Federation of Gynaecology and Obstetrics; HPV, human papillomavirus.